Be Part of the Future of Mental Health Care
Psychedelic research is moving quickly from small, early studies to large-scale clinical trials — and we are at the center of it all. If you live in the area and are interested in participating in psychedelic research studies, now is the time to get involved.
Clinically Media has launched Psychadelta, a community-driven initiative to connect patients, providers, and the public with trustworthy information about psychedelic research. By joining our group, you’ll receive updates on upcoming clinical trials enrolling and opportunities to participate.
Why Psychedelic Research Matters
In recent years, studies have shown that psychedelics like psilocybin (the active compound in “magic mushrooms”) and MDMA (sometimes known as Ecstasy or Molly) may have significant benefits for people looking for:
- Depression treatment
- Anxiety treatment
- PTSD (Post-Traumatic Stress Disorder) treatment
- Substance use disorders, including alcohol and opioids, treatment
- Trauma-related condition treatment
- Obsessive-compulsive disorder (OCD) treatment
- And other mental health treatment
While early results were promising, regulatory agencies required larger, randomized, multisite clinical trials to determine the safety and effectiveness of these treatments. Those studies are now producing the largest body of evidence to date — with major findings published in 2023–2024.
In fact, the U.S. Food and Drug Administration (FDA) has targeted August 2024 to decide on the first potential approval of MDMA-assisted therapy for PTSD, based on an application from Lykos Therapeutics.
This means psychedelic therapies may soon move from research settings to real-world treatment options — and we’re helping lead the way.
Clinical Trials: What You Need to Know
Clinical trials in the area are designed to test how psychedelic-assisted therapies may improve outcomes for patients who haven’t found relief with standard treatments.
By participating in a trial, you can:
- Gain access to cutting-edge potential therapies before they are widely available
- Contribute to groundbreaking science that could transform mental health care
- Help advance safe, responsible psychedelic research
Stay Informed with Psychadelta
Our Psychadelta group is designed to keep you connected. By signing up, you’ll get:
- Alerts when new psychedelic studies begin enrolling
- Updates on trial results and what they mean for patients and providers
- Opportunities to connect with medical professionals and others interested in psychedelic medicine
- Clear, accessible information about the risks and benefits of participating
Joining is free — and you’ll be the first to know when opportunities open up in your area.
Be Part of the Change
Psychedelic research is entering a new chapter. Whether you’re curious, hopeful, or ready to participate, Psychadelta is here to help you navigate the path forward.
Don’t miss your chance to be part of history.
Sign up now to receive updates on psychedelic research clinical trials.
